antigen
genet
characterist
swine
influenza
virus
siv
vari
differ
contin
region
world
siv
contain
hemagglutinin
ha
neuraminidas
na
gene
earli
recent
human
europ
siv
deriv
descend
hong
kong
pandem
viru
evolv
genet
reassort
endem
siv
result
siv
ha
na
gene
intern
north
america
virus
becom
establish
pig
popul
virus
tripl
reassort
ha
na
gene
human
virus
remain
gene
classic
swine
avian
multipl
siv
lineag
found
asia
ha
na
gene
deriv
human
virus
variou
time
slower
antigen
drift
ha
swine
virus
swine
time
becom
increasingli
diverg
contemporari
human
virus
exampl
european
siv
show
six
time
slower
rate
antigen
drift
human
consequ
european
siv
recent
year
still
show
degre
serolog
human
virus
human
virus
isol
swine
influenza
virus
usual
infect
human
sporad
zoonot
infect
report
siv
subtyp
infect
gener
mild
clinic
indistinguish
infect
human
influenza
virus
case
swine
influenza
occur
peopl
direct
indirect
exposur
swine
frequent
children
young
adult
european
siv
isol
girl
boy
netherland
close
relat
viru
also
isol
girl
hong
kong
north
america
nine
case
human
infect
tripl
reassort
siv
report
variant
origin
tripl
reassort
siv
contain
matrix
gene
pandem
viru
detect
human
unit
state
juli
april
case
us
state
juli
septemb
mainli
children
visit
counti
state
increas
number
human
case
may
part
due
heighten
awar
surveil
siv
far
shown
capac
spread
effici
human
alreadi
shortridg
et
suggest
pig
could
serv
reservoir
old
ahong
human
virus
virus
might
human
immun
wane
howev
remain
unknown
extent
immun
human
virus
may
offer
protect
siv
therefor
examin
effect
prior
infect
old
recent
human
influenza
viru
challeng
recent
european
siv
pig
model
repres
siv
enzoot
western
europ
human
influenza
virus
vaccin
refer
strain
respect
virus
propag
allanto
caviti
embryon
chicken
egg
less
four
passag
na
matrix
nucleoprotein
np
sequenc
compar
nucleotid
amino
acid
aa
level
use
megalign
program
within
dnastar
softwar
dnastar
inc
madison
wi
usa
addit
na
select
human
virus
circul
tabl
compar
amino
acid
differ
put
antigen
site
ha
na
defin
identifi
align
use
mega
softwar
http
wwwmegasoftwarenet
glycosyl
site
predict
netnglyc
web
server
http
wwwcbsdtudkservicesnetnglyc
describ
na
np
sequenc
studi
genbank
access
number
sequenc
use
comparison
download
genbank
character
hemagglutin
inhibit
hi
neuraminidas
inhibit
ni
test
use
ferret
hyperimmun
swine
sera
pig
obtain
influenza
farm
pig
randomli
assign
four
group
eight
pig
group
hous
separ
biosafeti
isol
unit
start
experi
pig
seroneg
european
endem
siv
determin
hi
test
immunoperoxidas
monolay
assay
competit
np
immunosorb
assay
idexx
laboratori
hoofddorp
netherland
acclim
week
three
group
inocul
respect
one
group
left
uninocul
serv
challeng
control
group
six
week
later
group
challeng
inocul
perform
intranas
egg
infect
dose
influenza
viru
ml
ml
per
nostril
describ
pig
observ
daili
clinic
sign
day
day
inocul
euthanasia
determin
viru
excret
nasal
swab
collect
daili
pig
day
inocul
dpi
day
dpc
euthanasia
four
pig
per
group
euthan
dpc
gross
lung
lesion
assess
describ
determin
extent
replic
challeng
viru
respiratori
tract
tissu
sampl
upper
nasal
mucosa
respiratori
part
olfactori
part
tonsil
trachea
lower
apic
cardiac
diaphragmat
lobe
left
right
lung
respiratori
tract
collect
titrat
separ
blood
sampl
serolog
examin
collect
start
experi
dpi
time
challeng
remain
pig
also
bled
dpc
cotton
swab
weigh
collect
determin
viru
titer
per
mg
nasal
secret
swab
nostril
suspend
ml
salin
supplement
fetal
bovin
serum
iuml
penicillin
streptomycin
mix
vigor
hour
tissu
sampl
weigh
ground
pb
contain
iuml
penicillin
streptomycin
obtain
wv
tissu
homogen
nasal
swab
sampl
tissu
homogen
clarifi
centrifug
g
minut
store
titrat
sampl
titrat
canin
kidney
mdck
cell
medium
trypsin
briefli
confluent
monolay
cell
inocul
serial
dilut
sampl
cell
wash
hour
inocul
subsequ
observ
develop
cytopath
effect
day
viru
titer
express
tissu
cultur
infect
dose
per
mg
nasal
swab
per
gram
tissu
serum
antibodi
respons
examin
hi
viru
neutral
vn
ni
test
sera
collect
dpi
dpc
examin
three
virus
hi
vn
test
sera
collect
dpc
test
ni
test
addit
vn
test
challeng
viru
perform
sera
collect
dpc
sera
heat
inactiv
minut
use
hi
test
perform
accord
standard
procedur
turkey
erythrocyt
hemagglutin
unit
vn
test
perform
mdck
cell
micropl
viru
per
well
previous
ni
test
base
colorimetr
analysi
sialic
acid
releas
fetuin
substrat
conduct
pcr
plate
describ
start
dilut
vn
test
hi
ni
test
nasal
viru
shed
group
quantifi
calcul
area
curv
auc
obtain
plot
viral
titer
versu
time
point
sampl
collect
sampl
test
neg
viru
given
numer
valu
per
mg
gram
sampl
test
neg
serolog
assay
assign
valu
correspond
half
minimum
detect
titer
test
use
compar
viru
titer
antibodi
level
two
experiment
group
p
consid
statist
signific
graphpad
prism
softwar
graphpad
softwar
inc
san
diego
ca
usa
use
analys
percentag
nucleotid
aa
ident
na
np
summar
tabl
na
similar
level
np
gene
human
virus
equal
similar
swine
viru
amino
acid
differ
presum
antigen
site
ha
shown
figur
segment
contain
aa
differ
compar
occur
recogn
antigen
site
antigen
site
b
c
e
contain
much
aa
differ
compar
fourteen
differ
locat
antigen
site
antigen
site
b
c
e
three
addit
site
globular
head
posit
found
absent
posit
locat
antigen
site
posit
receptor
bind
site
na
gene
also
close
relat
aa
differ
put
antigen
site
aa
differ
antigen
site
compar
one
addit
site
predict
posit
two
posit
tabl
compar
na
protein
sequenc
presum
antigen
site
addit
human
virus
collect
time
similar
start
human
strain
show
less
aa
homolog
swine
viru
aa
differ
antigen
site
ha
site
consist
present
globular
head
human
virus
examin
sinc
respect
na
similar
aport
human
virus
later
show
aa
homolog
swine
viru
aa
differ
antigen
site
na
tabl
show
antigen
relationship
ha
na
three
virus
use
studi
low
moder
observ
hi
ni
test
wherea
antisera
two
virus
lack
test
unknown
reason
ferret
serum
show
similar
ni
antibodi
titer
three
virus
swine
serum
show
minim
reaction
expect
intranas
inocul
pig
influenza
clinic
symptom
absent
pig
except
two
pig
dyspnea
dpi
pig
excret
viru
nasal
swab
viru
shed
detect
consecut
dpi
dpi
mean
viru
titer
nasal
swab
shown
figur
averag
auc
valu
highest
follow
pig
seroneg
three
virus
prior
start
experi
antibodi
titer
week
primari
inocul
shown
tabl
challeng
control
remain
seroneg
time
challeng
wherea
pig
develop
hi
vn
ni
antibodi
influenza
viru
use
inocul
homolog
antibodi
titer
significantli
higher
pig
pig
inocul
human
virus
p
except
hi
titer
dpi
p
inocul
induc
vn
antibodi
pig
hi
antibodi
detect
pig
dpi
ni
antibodi
pig
pig
serolog
neglig
vn
test
undetect
hi
ni
test
clinic
sign
observ
pig
challeng
infect
mean
titer
nasal
swab
shown
figur
viru
shed
detect
challeng
control
consecut
day
euthanasia
pig
group
test
neg
viru
excret
fail
prevent
challeng
infect
reduc
peak
viru
titer
nasal
swab
howev
mean
durat
nasal
shed
day
shorter
challeng
control
group
viru
titer
respiratori
tract
pig
euthan
dpc
shown
tabl
isol
nasal
mucosa
tonsil
trachea
left
lung
right
lung
challeng
control
pig
contrast
pig
group
complet
viru
neg
group
viru
isol
rate
viru
titer
similar
challeng
control
group
p
lung
lesion
character
consolid
area
involv
lung
surfac
present
two
challeng
control
pig
two
pig
absent
group
pig
challeng
control
group
develop
hi
vn
ni
antibodi
dpc
tabl
wherea
antibodi
titer
remain
level
group
p
pig
group
develop
antibodi
show
consider
increas
antibodi
titer
shown
figur
vn
antibodi
challeng
viru
develop
rapidli
group
challeng
control
group
group
similar
antibodi
titer
dpc
homolog
antibodi
titer
human
virus
also
increas
challeng
mani
pig
show
low
antibodi
titer
without
expos
rare
increas
antigen
diverg
virus
swine
human
may
import
implic
zoonot
transmiss
siv
first
studi
evalu
human
swine
virus
pig
show
complet
virolog
protect
infect
contemporari
european
siv
pig
infect
week
earlier
minim
protect
pig
recent
human
viru
identifi
immun
mechan
underli
observ
sever
find
point
toward
role
antibodi
ha
andor
na
swine
viru
inde
differ
protect
immun
respons
induc
two
human
virus
line
genet
antigen
differ
ha
na
antigen
site
b
locat
tip
ha
molecul
suppos
primari
target
neutral
differ
much
seven
total
nine
amino
acid
site
b
two
addit
site
make
distinct
addit
vn
antibodi
found
pig
previous
infect
rare
infect
howev
antibodi
develop
rapidli
pig
challeng
control
coincid
enhanc
clearanc
challeng
viru
hi
test
well
ni
test
less
sensit
vn
explain
lack
hi
ni
antibodi
pig
given
low
serum
antibodi
titer
pig
like
local
antibodi
respiratori
tract
immun
also
contribut
previou
studi
kyriaki
et
shown
siv
hi
test
hyperimmun
sera
human
virus
sera
present
comparison
human
virus
show
increas
genet
differ
sinc
reflect
increas
number
aa
differ
ha
na
addit
globular
head
suggest
especi
peopl
born
higher
risk
infect
european
siv
addit
vivo
studi
antigen
distinct
human
virus
would
requir
better
understand
natur
human
virus
could
offer
swine
virus
still
genet
antigen
analys
interpret
caution
test
result
serum
ferret
versu
swine
exampl
illustr
sera
differ
anim
speci
may
yield
discrep
result
definit
antigen
site
base
studi
oldest
human
virus
reaction
mous
monoclon
antibodi
question
whether
antigen
site
histor
virus
overlap
exactli
recent
human
swine
virus
furthermor
differ
anim
speci
like
mount
antibodi
recogn
differ
epitop
final
amino
acid
import
antigen
drift
other
accord
recent
studi
aa
posit
ha
larg
respons
antigen
evolut
human
virus
period
great
interest
identifi
immunodomin
amino
acid
ha
siv
human
virus
viru
titer
nasal
swab
antibodi
titer
serum
lower
pig
inocul
human
viru
pig
inocul
also
seem
replic
less
effici
pig
close
relat
virus
similar
find
made
compar
pig
infect
studi
tripl
reassort
siv
north
america
wholli
human
like
author
studi
suspect
lower
antibodi
respons
human
influenza
virus
pig
part
due
lower
replic
effici
viru
titer
ferret
model
also
differ
differ
viru
compar
studi
pathogenesi
human
swine
virus
pig
ferret
would
help
select
best
anim
model
experiment
condit
studi
virus
hand
separ
experi
laboratori
demonstr
complet
protect
pig
previous
infect
homolog
viru
condit
present
studi
similar
antibodi
titer
thu
human
virus
elicit
effici
protect
immun
respons
pig
recent
infect
human
unit
state
mainli
children
fair
set
variant
viru
v
swine
origin
rais
concern
extent
immun
viru
human
popul
serolog
studi
shown
hi
antibodi
late
adolesc
young
adult
wherea
antibodi
gener
lack
children
overal
serolog
find
present
studi
support
idea
variou
siv
lineag
could
caus
pandem
younger
popul
acquir
capac
spread
effici
peopl
v
phylogenet
close
relat
human
virus
era
slightli
relat
human
virus
centuri
european
therefor
assum
immun
statu
young
peopl
may
even
lower
european
siv
v
serolog
investig
human
experiment
studi
well
studi
host
barrier
need
explor
suscept
human
variou
siv
experiment
studi
perform
artifici
condit
assess
arm
immun
respons
true
protect
mani
serolog
studi
consid
subject
hi
titer
protect
may
therefor
underestim
protect
siv
human
popul
